Melissa Martinez1, Julia LeBlanc1, Mohammad Al-Haddad1, Stuart Sherman1, John DeWitt1. 1. Melissa Martinez, Julia LeBlanc, Mohammad Al-Haddad, Stuart Sherman, John DeWitt, Department of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202, United States.
Abstract
AIM: To report the clinical impact of adrenal endoscopic ultrasound fine-needle aspiration (EUS-FNA) in the evaluation of patients with adrenal gland enlargement or mass. METHODS: In a retrospective single-center case-series, patients undergoing EUS-FNA of either adrenal gland from 1997-2011 in our tertiary care center were included. Medical records were reviewed and results of EUS, cytology, adrenal size change on follow-up imaging ≥ 6 mo after EUS and any repeat EUS or surgery were abstracted. A lesion was considered benign if: (1) EUS-FNA cytology was benign and the lesion remained < 1 cm from its original size on follow-up computed tomography (CT), magnetic resonance imaging or repeat EUS ≥ 6 mo after EUS-FNA; or (2) subsequent adrenalectomy and surgical pathology was benign. RESULTS: Ninety-four patients had left (n = 90) and/or right (n = 5) adrenal EUS-FNA without adverse events. EUS indications included: cancer staging or suspected recurrence (n = 31), pancreatic (n = 20), mediastinal (n = 10), adrenal (n = 7), lung (n = 7) mass or other indication (n = 19). Diagnoses after adrenal EUS-FNA included metastatic lung (n = 10), esophageal (n= 5), colon (n = 2), or other cancer (n = 8); benign primary adrenal mass or benign tissue (n = 60); or was non-diagnostic (n = 9). Available follow-up confirmed a benign lesion in 5/9 non-diagnostic aspirates and 32/60 benign aspirates. Four of the 60 benign aspirates were later confirmed as malignant by repeat biopsy, follow-up CT, or adrenalectomy. Adrenal EUS-FNA diagnosed metastatic cancer in 24, and ruled out metastasis in 10 patients. For the diagnosis of malignancy, EUS-FNA of either adrenal had sensitivity, specificity, positive predictive value and negative predictive value of 86%, 97%, 96% and 89%, respectively. CONCLUSION: Adrenal gland EUS-FNA is safe, minimally invasive and a sensitive technique with significant impact in the management of adrenal gland mass or enlargement.
AIM: To report the clinical impact of adrenal endoscopic ultrasound fine-needle aspiration (EUS-FNA) in the evaluation of patients with adrenal gland enlargement or mass. METHODS: In a retrospective single-center case-series, patients undergoing EUS-FNA of either adrenal gland from 1997-2011 in our tertiary care center were included. Medical records were reviewed and results of EUS, cytology, adrenal size change on follow-up imaging ≥ 6 mo after EUS and any repeat EUS or surgery were abstracted. A lesion was considered benign if: (1) EUS-FNA cytology was benign and the lesion remained < 1 cm from its original size on follow-up computed tomography (CT), magnetic resonance imaging or repeat EUS ≥ 6 mo after EUS-FNA; or (2) subsequent adrenalectomy and surgical pathology was benign. RESULTS: Ninety-four patients had left (n = 90) and/or right (n = 5) adrenal EUS-FNA without adverse events. EUS indications included: cancer staging or suspected recurrence (n = 31), pancreatic (n = 20), mediastinal (n = 10), adrenal (n = 7), lung (n = 7) mass or other indication (n = 19). Diagnoses after adrenal EUS-FNA included metastatic lung (n = 10), esophageal (n= 5), colon (n = 2), or other cancer (n = 8); benign primary adrenal mass or benign tissue (n = 60); or was non-diagnostic (n = 9). Available follow-up confirmed a benign lesion in 5/9 non-diagnostic aspirates and 32/60 benign aspirates. Four of the 60 benign aspirates were later confirmed as malignant by repeat biopsy, follow-up CT, or adrenalectomy. Adrenal EUS-FNA diagnosed metastatic cancer in 24, and ruled out metastasis in 10 patients. For the diagnosis of malignancy, EUS-FNA of either adrenal had sensitivity, specificity, positive predictive value and negative predictive value of 86%, 97%, 96% and 89%, respectively. CONCLUSION: Adrenal gland EUS-FNA is safe, minimally invasive and a sensitive technique with significant impact in the management of adrenal gland mass or enlargement.
Authors: Olga C J Schuurbiers; Kurt G Tournoy; Hans J Schoppers; Bernadette G Dijkman; Henri J L M Timmers; Lioe-Fee de Geus-Oei; Johanna M M Grefte; Klaus F Rabe; P N Richard Dekhuijzen; Henricus F M van der Heijden; Jouke T Annema Journal: Lung Cancer Date: 2011-01-31 Impact factor: 5.705
Authors: M G Harisinghani; M M Maher; P F Hahn; D A Gervais; K Jhaveri; J Varghese; P R Mueller Journal: Clin Radiol Date: 2002-10 Impact factor: 2.350
Authors: S Uemura; I Yasuda; T Kato; S Doi; J Kawaguchi; T Yamauchi; Y Kaneko; R Ohnishi; T Suzuki; S Yasuda; K Sano; H Moriwaki Journal: Endoscopy Date: 2013-01-08 Impact factor: 10.093
Authors: Tiing Leong Ang; Tju Siang Chua; Kwong Ming Fock; Augustine K H Tee; Eng Kiong Teo; Kent Mancer Journal: Ann Acad Med Singapore Date: 2007-11 Impact factor: 2.473
Authors: Everton Hadlich; Augusto P C Carbonari; Maurício S Assef; Osvaldo M Araki; Frank S Nakao; Mauro T A Saieg; Lúcio G B Rossini Journal: Endosc Ultrasound Date: 2017 Mar-Apr Impact factor: 5.628
Authors: A Martin-Cardona; G Fernandez-Esparrach; J C Subtil; J Iglesias-Garcia; M Garcia-Guix; A Barturen Barroso; A Z Gimeno-Garcia; J M Esteban; A Pardo Balteiro; A Velasco-Guardado; E Vazquez-Sequeiros; C Loras; B Martinez-Moreno; A Castellot; C Huertas; M Martinez-Lapiedra; A Sanchez-Yague; A Teran; V J Morales-Alvarado; M Betes; D de la Iglesia; C Sánchez-Montes; M D Lozano; J Lariño-Noia; A Gines; C Tebe; J B Gornals Journal: PLoS One Date: 2019-06-06 Impact factor: 3.240